Peter has more than 20 years of executive leadership experience in the biotech industry, from private start-ups to established publicly traded companies, scaling companies through key financings and pharma partnerships, advancing novel therapeutics from scientific breakthrough to the clinic, and commercializing FDA-approved medicines. Prior to joining Arialys, Peter was Cofounder and Chief Operating Officer of Artiva Biotherapeutics, where he oversaw business development and strategy, research, manufacturing, and corporate operations. During his time at Artiva, the company achieved significant financing, clearance of several IND applications, the establishment of a built-to-fit office, research labs, and internal GMP manufacturing capability, and corporate partnerships with Merck and Affimed. Prior to Artiva, Peter was the Global Head of Development and a senior executive at Orexigen, where he oversaw the post-marketing development and regulatory aspects of Contrave®, an FDA-approved weight-loss prescription medication. Coordinating staff across the U.S., E.U., and MENA regions, he collaborated with the commercial team to ensure effective medical and regulatory support for global partnerships and direct-to-consumer and telemedicine campaigns for Contrave. Prior to Orexigen, Peter was Senior Vice President, Early Program Development at Fate Therapeutics, where he was responsible for the development of the iPSC platform and was a member of the senior executive team for Fate’s IPO in 2013. Prior to Fate, he was Vice President of Research at Ren Pharmaceuticals. Peter started his industry career at the antibody therapeutics company KaloBios, where as head of biochemistry he helped build both the platform technology and therapeutic pipeline. Peter received a Ph.D. in biochemistry from the Imperial Cancer Research Fund / University College London and was a postdoctoral fellow at the University of California, San Francisco.